Climb Bio Inc 2026年季度报告

FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from to CLIMB BIO, INC. (Exact Name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Table of Contents PART I.FINANCIAL INFORMATION Item 1.Condensed Consolidated Financial Statements (unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Stockholders’ EquityCondensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results and OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (Quarterly Report) contains forward-looking statements within the meaning of the U.S. PrivateSecurities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21Eof the Securities Exchange Act of 1934, as amended (Exchange Act), that involve substantial risk and uncertainties. All statements,other than statements of historical fact, contained in this Quarterly Report, including statements regarding our strategy, futureoperations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expectedmarket growth, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,”“expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similarexpressions are intended to identify forward-looking statements, although not all forward-looking statements contain theseidentifying words. The forward-looking statements in this Quarterly Report include, among other things, statements about: •the initiation, timing, progress and results of our research and development programs, nonclinical studies and clinicaltrials;•the anticipated timing of the submission and clearance of investigational new drug applications (IND) and comparableforeign applications for budoprutug and CLYM116;•our estimates regarding the potential patient populations for our product candidates;•our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the period overwhich we believe our cash, cash equivalents and marketable securities, including the proceeds from our privateplacement in April 2026, will be sufficient to fund our operating expenses and capital expenditure requirements;•our plans to develop and, if approved, subsequently commercialize our product candidates;•the timing of and our ability to submit applications for, and obtain and maintain regulatory approvals for our productcandidates;•our intellectual property position and our expectations regarding our ability to obtain, maintain and enforce intellectualproperty protection for our product candidates;•our estimates regarding the size of the potential markets for our product candidates and our